Читать книгу Transporters and Drug-Metabolizing Enzymes in Drug Toxicity - Albert P. Li - Страница 94

Trovafloxacin is a fluoroquinolone (FQ) with broad spectrum antibiotic properties. Trovafloxacin inhibits two key enzymes for bacterial cell replication: (i) DNA gyrase, an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA; and (ii) Topoisomerase IV, an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division [233, 234]. FQ drugs have the potential to be effective toward bacteria that are resistant to commonly used antibiotics (e.g. penicillins, cephalosporins, aminoglycosides, macrolides, and tetracyclines) that have different mechanism of action.

Trovafloxacin was approved by FDA in 1997. In 1999, FDA placed limits on its application due to its association with 140 reports of hepatic events [235–237] and, including 14 cases of hepatic failure, leading to 6 deaths [235].